Rabivas-LS
RABIVAS-LS is a combination of Rabeprazole, a proton pump inhibitor (PPI), and Levosulpiride, a prokinetic agent, formulated in a sustained-release (SR) capsule. This dual-action formulation effectively manages acid-related gastrointestinal disorders, addressing both acid secretion and motility issues, making it ideal for conditions such as GERD and functional dyspepsia.
- Recommended Usage
Indications
- Gastroesophageal Reflux Disease (GERD): Treats acid reflux and associated symptoms like heartburn, regurgitation, and chest discomfort.
- Functional Dyspepsia: Provides relief from symptoms such as bloating, nausea, and fullness due to gastric motility disorders.
- Peptic Ulcers: Heals stomach and duodenal ulcers, especially when associated with impaired gastric emptying.
- Erosive Esophagitis: Reduces esophageal inflammation caused by acid reflux.
- Delayed Gastric Emptying: Levosulpiride enhances gastric motility, helping to relieve symptoms of nausea and fullness.
Dosage and Administration
Route of Administration: Oral sustained-release capsule.
Typical Dose for Adults: One capsule daily, preferably 15-30 minutes before meals, or as directed by a healthcare provider.
Administration: Swallow the capsule whole with water. Do not chew, crush, or split the capsule to ensure proper sustained-release action.
Precautions
Hypersensitivity: Avoid use in patients allergic to Rabeprazole, Levosulpiride, or any other component of the formulation.
Pregnancy and Breastfeeding: Consult a healthcare provider before using during pregnancy or breastfeeding.
Drug Interactions: Rabeprazole may interact with drugs that alter the stomach's pH or liver enzymes. Levosulpiride may interact with other prokinetic agents or medications affecting the QT interval.
Liver or Kidney Impairment: Use cautiously in patients with hepatic or renal dysfunction. Dose adjustments may be required.
Prolonged Use: Extended use of PPIs like Rabeprazole may lead to vitamin B12 deficiency, magnesium deficiency, and increased fracture risk. Levosulpiride should be used cautiously in patients with a history of movement disorders.
Benefits
Dual Mechanism of Action: Rabeprazole effectively suppresses acid production, while Levosulpiride improves gastric motility and reduces nausea and bloating.
Sustained-Release Formula: Provides long-lasting symptom relief throughout the day.
Comprehensive Relief: Treats both acid reflux and motility issues in conditions like GERD and functional dyspepsia.
Improves Gastric Emptying: Levosulpiride helps alleviate symptoms of delayed gastric emptying, such as nausea and fullness.
Well-Tolerated: Designed for easy administration with minimal side effects when used as prescribed.
